



Atty. Dkt. No. 087147-0494

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re reissue application of: U.S. Pat. No. 6,348,481, issued February 19, 2002

Applicants: Yoshiyuki INADA et al.

Title: PHARMACEUTICAL COMPOSITION FOR ANGIOTENSIN II-MEDIATED DISEASES

Appl. No.: 10/781,263

Filing Date: 02/19/2004

Examiner: Sun Jae Y. LOEWE

Art Unit: 1626

Conf. No.: 3131

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Your Petitioner, TAKEDA PHARMACEUTICAL COMPANY LIMITED, having its principal place of business at 1-1-Doshomachi 4-chome, Chuo-ku, Osaka, JAPAN, represents that it is the owner of the entire right, title, and interest in and to U.S. Patent Application No. 10/781,263, filed 02/19/2004, a reissue of U.S. Patent No. 6,384,481, which is based on Application No. 09/758,355, filed on January 12, 2001, by virtue of an Assignment recorded on Reel/Frame 015612/0101, in the United States Patent and Trademark Office, a copy of the Patent Assignment Abstract is attached hereto as APPENDIX A.

09/11/2008 AWONDAF1 00000016 10781263

04 FC:1014

130.00 OP

Further, your Petitioner represents that it is the owner of U.S. Patent No. 6,420,405, which issued on U.S. Patent Application No. 09/783,579, filed February 15, 2001, by virtue of an Assignment recorded on Reel/Frame 015612/0101, in the United States Patent and Trademark Office, a copy of the Patent Assignment Abstract of Title is attached hereto as APPENDIX B.

Your Petitioner, TAKEDA PHARMACEUTICAL COMPANY LIMITED, hereby disclaims the terminal part of the term of any patent granted on the above identified patent application which would extend beyond the full statutory term, as shortened by any terminal disclaimer, of U.S. Patent 6,420,405, and hereby agrees that any patent so granted on the above identified patent application shall be enforceable only for and during such period that the legal title to U.S. Patent 6,420,405 shall be the same as the legal title to any patent granted on the above identified patent application, this agreement to run with any patent granted on the above identified patent application and to be binding upon the grantee, its successors or assigns.

In making the above disclaimer, Petitioner does not disclaim any terminal part of any patent granted on the above identified patent application, prior to the full statutory term of U.S. Patent 6,420,405 as defined in 35 U.S.C. §§ 154-156 and 173, in the event that U.S. Patent 6,420,405 expires for failure to pay a maintenance fee, is held unenforceable or is found invalid in a final judgment by a court of competent jurisdiction, are statutorily disclaimed in whole or terminally disclaimed under 37 CFR § 1.321(a), has all claims canceled by a reexamination certificate or as a result of an interference proceeding, or is otherwise not deemed to provide the rights conveyed by 35 USC § 154, prior to the full statutory term of U.S. Patent 6,420,405, as defined in 35 USC §§ 154-156 and 173, except for the separation of legal title stated above. Further, Petitioner does not disclaim any terminal part of a patent granted on the above identified patent application that would extend beyond the present termination of U.S. Patent 6,420,405, in the event that such present term is extended by virtue of compliance with the conditions for term extension of any present or future patent term extension provisions of the patent law, including but not limited to 35 U.S.C. §§ 155, 155A or 156, and without waiving Petitioner's right to extend the term of a patent granted on the above identified patent application to the extent provided by law.

The undersigned, being the Attorney of Record for the above identified patent application, and duly authorized to act on behalf of Petitioner, certifies that he has reviewed the Assignments attached as APPENDICES A and B, and to the best of his knowledge and belief, legal titles to the above identified patent application and U.S. Patent 6,420,405, rests with Petitioners, TAKEDA PHARMACEUTICAL COMPANY LIMITED.

The undersigned declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the above-identified application or any patent issuing therefrom.

Respectfully submitted,

Date Sept. 9, 2008

By Stephen B. Maebius

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5569
Facsimile: (202) 672-5399

Stephen B. Maebius
Attorney for Applicants
Registration No. 35,264



United States Patent and Trademark Office

[Home](#) | [Site Index](#) | [Search](#) | [Guides](#) | [Contacts](#) | [eBusiness](#) | [eBiz alerts](#) | [News](#) | [Help](#)

Assignments on the Web > Patent Query

Patent Assignment Abstract of Title

**NOTE: Results display only for issued patents and published applications.
For pending or abandoned applications please consult USPTO staff.**

Total Assignments: 1

Patent #: 6348481

Issue Dt: 02/19/2002

Application #: 09758355

Filing Dt: 01/12/2001

Publication #: 20010004640

Pub Dt: 06/21/2001

Inventors: Yoshiyuki Inada, Keiji Kubo

Title: Pharmaceutical composition for angiotensin II-mediated diseases

Assignment: 1

Reel/Frame: 015612/0101

Recorded: 01/19/2005

Pages: 13

Conveyance: CHANGE OF NAME (SEE DOCUMENT FOR DETAILS).

Assignor: TAKEDA CHEMICAL INDUSTRIES, LTD.

Exec Dt: 06/29/2004

Assignee: TAKEDA PHARMACEUTICAL COMPANY, LIMITED

1-1, DOSHOMACHI 4-CHOME

CHUO-KU, OSAKA, JAPAN

Correspondent: DAVID J. CUSHING

2100 PENNSYLVANIA AVENUE, N.W.

SUITE 800

WASHINGTON, DC 20037

Search Results as of: 09/08/2008 01:21 PM

If you have any comments or questions concerning the data displayed, contact PRD / Assignments at 571-272-3350. v.2.0.1
Web interface last modified: April 20, 2007 v.2.0.1

[HOME](#) | [INDEX](#) | [SEARCH](#) | [eBUSINESS](#) | [CONTACT US](#) | [PRIVACY STATEMENT](#)



United States Patent and Trademark Office

[Home](#) | [Site Index](#) | [Search](#) | [Guides](#) | [Contacts](#) | [eBusiness](#) | [eBiz alerts](#) | [News](#) | [Help](#)

Assignments on the Web > Patent Query

Patent Assignment Abstract of Title

**NOTE: Results display only for issued patents and published applications.
For pending or abandoned applications please consult USPTO staff.**

Total Assignments: 1

Patent #: [6420405](#)

Issue Dt: 07/16/2002

Application #: 09783579

Filing Dt: 02/15/2001

Publication #: [20010011098](#)

Pub Dt: 08/02/2001

Inventors: Yoshiyuki Inada, Keiji Kubo

Title: PHARMACEUTICAL COMPOSITION FOR ANGIOTENSIN II-MEDIATED DISEASES

Assignment: 1

Reel/Frame: [015612/0101](#)

Recorded: 01/19/2005

Pages: 13

Conveyance: CHANGE OF NAME (SEE DOCUMENT FOR DETAILS).

Assignor: [TAKEDA CHEMICAL INDUSTRIES, LTD.](#)

Exec Dt: 06/29/2004

Assignee: [TAKEDA PHARMACEUTICAL COMPANY, LIMITED](#)

1-1, DOSHOMACHI 4-CHOME

CHUO-KU, OSAKA, JAPAN

Correspondent: DAVID J. CUSHING

2100 PENNSYLVANIA AVENUE, N.W.

SUITE 800

WASHINGTON, DC 20037

Search Results as of: 09/08/2008 01:12 PM

If you have any comments or questions concerning the data displayed, contact PRD / Assignments at 571-272-3350. v.2.0.1
Web interface last modified: April 20, 2007 v.2.0.1

[| .HOME](#) | [INDEX](#) | [SEARCH](#) | [eBUSINESS](#) | [CONTACT US](#) | [PRIVACY STATEMENT](#)

2008年6月16日
(全1枚)

666-0037
兵庫県川西市松ヶ丘町3-6
稲田 義行 様

大阪市淀川区十三本町二丁目17番85号
武田薬品工業株式会社 知的財産部
シニアマネージャー 長谷川 吉一
担当 藤川 直人
Tel.06-6300-6428 Fax.06-6300-6601

特許出願Case2162US8N(TCV-116C・利尿剤合剤)の宣誓書手続きについてのお願い

前略

稲田様が発明者である題記の特許出願につき、米国特許庁におきまして再発行手続をするに際し、稲田様にサインいただいた宣誓書を提出する必要があります。宣誓書について直接説明差し上げた上でサインを頂きたいと考えておりますので、ご都合のよろしい時間帯に担当・藤川までご連絡いただきますようお願い申し上げます。

大変恐縮ですが、6月25日までにご連絡のほどお願いいたします。

草々

Naoto Fujikawa

June 16th, 2008

(1 sheet in all)

Dr. Yoshiyuki Inada,
3-6, Matsugaoka-Cho,
Kawanishi-City,
Hyogo, Japan

17-85, Jusohonmachi 2-Chome,
Yodogawa-Ku, Osaka, Japan
Takeda Pharmaceutical Company, Ltd.
Intellectual Property Department
Senior Manager : Yoshikazu Hasegawa
Administrator: Naoto Fujikawa

**Requests regarding the Declaration Procedure of Case2162US8N(TCV-116C/diuretics
combination)**

(Case2162US8N is Takeda's Ref.No. of US Appl.No. 10/781,263)

Dear Sirs,

With regard to the aforementioned patent application, please be noted that it is necessary to file the Declaration Form which is sealed and signed by inventors in order to file a reissue application to USPTO. We would like you to sign the Form after we explain face-to-face the detail of the Declaration, so please contact Mr. Fujikawa at your convenience.

I wouldn't like to bother you, but we would like to talk with you by June 25th.

Best regards,

この郵便物は、6月10日に配達に回りましたが不在のため留置で戻りし
 ためとやり直しを繰り返した上、保管期限満了日の翌日に再配達を求めたが返却
 いたしませんでしたので返却しさせていただきます。
 なお、次回配達に当たっては、受取人さまの電話番号についてご記入を
 お願いいたします。

1. 月 日()日 受取いたなくお電話連絡しました。
 2. 月 日()日 受取いたなくお電話連絡しました。
 3. 6月20日()日 受取いたなくお電話連絡しました。 同封返信

20. 26

↓ English translation

We tried to deliver this mail to your mentioned address above on June 18th, however, we couldn't do it due to the addressee's absence.


We tried to deliver again one week later but we couldn't do it again due to the same reason. Sorry but we have to return this mail to you. We have left a notice in the addressed mail box as below.

When you mail again, please let us know addressee's phone number if you know it.

(notification) 1. I have called and asked you to receive the mail after (month/day).

2. I have let you know that you should receive this mail again on (month/day).
 3. I have tried to deliver this mail to you on June 26th again.

(Kawanishi-City Post Office)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No. 087147-0494

Reissue Application No. 10/781,263

In re patent of Yoshiyuki INADA

U.S. Patent No. 6,348,481

Issued: February 19, 2002

Filed: 2/19/2004

Examiner: Sun Jae Y. Loewe

Art Unit: 1626

For: PHARMACEUTICAL COMPOSITION FOR ANGIOTENSIN II-MEDIATED DISEASES

CONSENT OF ASSIGNEE and
CERTIFICATE UNDER 37 CFR § 3.73(b)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Takeda Pharmaceutical Company Limited certifies that it is the assignee of the above-identified application by virtue of an assignment from Yoshiyuki Inada and Keiji Kubo recorded in the Patent and Trademark Office on February 22, 1995, in grandparent application 08/351,011, at Reel 7364, Frame 0232; and a change of name from Takeda Chemical Industries, Ltd. to Takeda Pharmaceutical Company Limited recorded in the present application at Reel 015864, Frame 0954.

The undersigned is empowered to sign this Certificate on behalf of the assignee.

Takeda Pharmaceutical Company Limited, by the undersigned authorized representative, hereby consents to the accompanying Petition under 37 C.F.R. § 1.47(a) and 37 C.F.R. § 1.182, to accept the Substitute Reissue Declaration and response filed simultaneously herewith, without the signature of inventor Yoshiyuki Inada, in view of the facts presented in the Petition.

The undersigned hereby declares that all statements made herein of his own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under

Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing therefrom.

Takeda Pharmaceutical Company Limited

Date: September 8, 2008

Yoshiaki Okumura
NAME Yoshiaki Okumura

Intellectual Property Dept.
TITLE General Manager